Publications
Detailed Information
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Park, In Ae | - |
dc.date.accessioned | 2022-03-22T09:11:29Z | - |
dc.date.available | 2022-03-22T09:11:29Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.created | 2021-05-14 | - |
dc.date.created | 2021-05-14 | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2013-11 | - |
dc.identifier.citation | Cancer Chemotherapy and Pharmacology, Vol.72 No.5, pp.1023-1029 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.other | 131315 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177232 | - |
dc.description.abstract | Epidermal growth factor (EGF) is a ligand for the epidermal growth factor receptor (EGFR). Human epidermal growth factor receptor 2 (HER2) shares common signal pathways and forms a heterodimer with EGFR. In this study, we investigated the clinical and pathologic implications of serum EGF levels in patients with HER2-positive metastatic breast cancer (MBC). We analyzed serum EGF levels from baseline serum samples of consecutive patients with HER2-positive MBC who received first-line trastuzumab plus taxane chemotherapy and correlated them with treatment outcomes and pathologic features. A total of 50 women were analyzed. The median age was 47 years (range 27-72 years). Patients with high serum EGF levels (a parts per thousand yen10.0 pg/mL) had significantly longer overall survival (47.0 months (95 % confidence interval (CI) 28.3-65.7 months) vs. 23.3 months (95 % CI 13.5-33.1 months); p = 0.009) with a tendency toward longer progression-free survival (p = 0.123). Serum EGF levels were not associated with hematologic or cardiac adverse events. Progesterone receptor-positive patients had significantly higher serum EGF levels than progesterone receptor-negative patients (24.3 pg/mL (range 9.5-69.0 pg/mL) vs. 12.3 pg/mL (range 0.0-59.5 pg/mL); p = 0.006). Our data suggest that high serum EGF levels may be associated with good prognosis in patients with HER2-positive MBC receiving trastuzumab plus taxane chemotherapy. In addition, serum EGF levels were associated with progesterone receptor positivity. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s00280-013-2268-9 | - |
dc.citation.journaltitle | Cancer Chemotherapy and Pharmacology | - |
dc.identifier.wosid | 000326100400009 | - |
dc.identifier.scopusid | 2-s2.0-84887173054 | - |
dc.citation.endpage | 1029 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 1023 | - |
dc.citation.volume | 72 | - |
dc.identifier.sci | 000326100400009 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | FACTOR GENE-EXPRESSION | - |
dc.subject.keywordPlus | PROGESTERONE-RECEPTOR | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | ERBB-2 | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordPlus | ESTROGEN | - |
dc.subject.keywordPlus | LIGANDS | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | EGF | - |
dc.subject.keywordAuthor | Epidermal growth factor | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Trastuzumab | - |
dc.subject.keywordAuthor | Taxane | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Hormone receptor | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.